| Literature DB >> 20644120 |
Jayesh Mehta1, Michele Cavo, Seema Singhal.
Abstract
The clinical approach to older patients with myeloma has to be modified to take into account comorbidities and the likelihood of higher treatment-related toxicity. Individualization of management and adequate supportive therapy are important to obtain the best response while minimizing adverse effects. Corticosteroids, novel agents, conventional cytotoxic agents, and high-dose chemotherapy with autotransplantation (modalities used in younger patients) are also used in older patients, although the elderly undergo transplantation less frequently. The sequential use of active agents singly and in different combinations has improved response rates and survival of all patients with myeloma, including the elderly.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20644120 DOI: 10.1182/blood-2009-10-163329
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113